Senza categoria Archives - Page 5 of 13 - Elixi International

9 February 2021

Breyanzi (lisocabtagene maraleucel), new Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma

26 January 2021

RINVOQ™ (Upadacitinib), approved for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis

19 January 2021

XALKORI (CRIZOTINIB) approved for ALK-POSITIVE anaplastic large cell LYMPHOMA in children and young adults

18 January 2021

Enhertu (trastuzumab deruxtecan) first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer

12 January 2021

Xofluza® (baloxavir marboxil), a first-in-class, single-dose oral medicine, for the treatment of influenza,

8 January 2021

Glucagon for injection USP, First Generic of Drug Used to Treat Severe Hypoglycemia

5 January 2021

Ibrance, Palbociclib, is the #1 prescribed, FDA-approved oral combination treatment for HR+, HER2- mBC.

22 December 2020

Libmeldy, world’s first lentiviral vector-based gene therapy for the treatment of metachromatic leukodystrophy (MLD)

21 December 2020

PALFORZIA® [defatted powder of Arachis hypogaea L., semen (peanuts)]approved in the EU for the treatment of peanut allergy

19 December 2020

Tagrisso (osimertinib) , First Adjuvant Therapy for Most Common Type of Lung Cancer